LNP DELIVERY SYSTEM
Cosychem has an independently owned ionizable lipid library with intellectual property rights, which can cover over 10000 types of lipid structures. Efficient and specific in vivo delivery of liver, lung, spleen, and muscle tissues can be achieved through structural or formulation adjustments. In vivo toxicity testing shows that Cosychem high-quality lipids have a safety window for compound use that is 50-100 times higher. We can provide customers with various nucleic acid drugs (siRNA, mRNA), gene editing, gene regulation therapy, and delivery solutions targeting different organs.
低毒性
稳定性强
靶向器官递送
肝外递送
类型载荷兼容性
GMP可放大生产能力
自主知识产权
LIPID NANOPARTICLE (LNP) SERVICES
Targeted LNP Structure and Formula Design
Optimize lipid structure, formulation composition, particle size, and surface modification for different types of nucleic acids (mRNA, siRNA, circular RNA, etc.) and indications (vaccines, tumor immunity, gene editing) to enhance targeting and stability.
Preparation and Process Optimization of LNPs
Utilizing microfluidic technology for large-scale synthesis of LNPs, supporting laboratory trials (μg level) to clinical production (g level), ensuring batch consistency.
Stability and safety assessment
Provide in vitro stability testing, in vitro safety assessment, and toxicity evaluation of LNP to reduce immunogenicity and off target risks.
Synthesis and structural customization of LNPs
Cosychem provides customized chemical structure design services for the four components of LNPs (ionizable lipids, auxiliary lipids, cholesterol, PEG lipids), supporting the synthesis of specific molecular libraries and the development of derivatives.
Intellectual Property Services
The LNP delivery system based on independent intellectual property rights offers evaluation licensing for cationic lipids and LNP formulations, as well as customized proprietary transformation services.
LNP DELIVERY SYSTEM
DownLoadGALNAC DELIVERY SYSTEM
GALNAC DELIVERY SYSTEM
DownLoad
Introduction
GalNAc nucleic acid conjugates are divided into three parts: a three contact GalNAc target, a connecting arm, and a small nucleic acid molecule. GalNAc is covalently conjugated to the 3 'end of the sense chain of siRNA of different sequences in a trivalent state, forming polysaccharide siRNA single conjugates for direct and targeted delivery.
Delivery principle
GalNAc is a ligand for the asialoglycoprotein receptor (ASGPR), which can specifically bind to it. ASGPR and clathrin mediated endocytosis can effectively transport it to the cytoplasm, achieving rapid cellular endocytosis.
Custom Synthesis
CAS No：1159408-54-4
Purity：98%
Scale：10g,100g,kg